fbpx

Cyxone – Introduction to the share

Cyxone - Introduction to the share 29 AprilApr 2022 11:00 - 11:30 Europe/CopenhagenOnline Event

Cyxone – Introduction to the share

Cyxone, a swedish based biotech company active within the area of autoimmune diseases will participate at a digital event hosted by HC Andersen Capital on Friday April 29th where the CEO of Cyxone Tara Heitner will present to give an introduction of the company. Cyxone develops therapies for the two autoimmune diseases rheumatoid arthritis (RA) and multiple sclerosis, where its primary product candidate, Rabexiomed, for RA is in phase 2 and T20K for multiple sclerosis is in Phase 1.
At the event you will get the opportunity to hear more about Cyxone and its product pipeline. Topics for questions and discussion could be the upcoming phase 2b study for RA, the market opportunity for its product candidates and potential for multi-indication of Rabexiomed, its partner and licensing strategy as well as the financial position of the company following the recent rights issue where Cyxone raised more than SEK 60 million.
*HC Andersen Capital receives payment from Cyxone for a DigitalIR/Corporate Visibility agreement.

Deltag her

Du vil blive videresendt til en ekstern tilmeldingsside. 

Information

Cyxone - Introduction to the share 29 AprilApr 2022 11:00 - 11:30 Europe/Copenhagen
Cyxone - Introduction to the share Online Event
Cyxone